B. Braun unveils a portfolio of magnesium sulfate ready-to-use injectable drug products, indicated for the prevention and control of seizures associated with preeclampsia and eclampsia. Doses include magnesium sulfate in 5% dextrose, 1 g/100 mL; magnesium sulfate in water, 2 g/50 mL; magnesium sulfate in water, 4 g/50 mL; and magnesium sulfate in water, 4 g/100 mL. The infusion bags are made without rubber latex, PVC, or DEHP. Furthermore, the infusion bags do not require an overwrap, which reduces landfill waste. The magnesium sulfate products are domestically manufactured and produced with American-made active pharmaceutical ingredients, helping ensure consistent supply levels.